Short Interest in AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Declines By 69.9%

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) saw a large decline in short interest during the month of January. As of January 15th, there was short interest totaling 61,954 shares, a decline of 69.9% from the December 31st total of 205,893 shares. Approximately 2.2% of the company’s shares are sold short. Based on an average daily volume of 77,286 shares, the days-to-cover ratio is currently 0.8 days. Based on an average daily volume of 77,286 shares, the days-to-cover ratio is currently 0.8 days. Approximately 2.2% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded shares of AIM ImmunoTech from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 8th. Two equities research analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Strong Buy”.

AIM ImmunoTech Trading Up 0.8%

AIM stock traded up $0.01 during mid-day trading on Wednesday, hitting $1.22. 141,929 shares of the company were exchanged, compared to its average volume of 104,897. The business has a fifty day simple moving average of $1.34 and a 200-day simple moving average of $2.54. AIM ImmunoTech has a 12-month low of $1.07 and a 12-month high of $36.00.

AIM ImmunoTech (NYSEAMERICAN:AIM) last released its quarterly earnings results on Monday, November 17th. The company reported ($1.57) earnings per share (EPS) for the quarter. The firm had revenue of $0.03 million for the quarter. On average, analysts predict that AIM ImmunoTech will post -0.3 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in AIM ImmunoTech stock. Corient Private Wealth LLC acquired a new stake in AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 10,001 shares of the company’s stock, valued at approximately $87,000. Corient Private Wealth LLC owned approximately 0.37% of AIM ImmunoTech at the end of the most recent quarter. Hedge funds and other institutional investors own 12.02% of the company’s stock.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.